Anbio Biotechnology Class A Ordinary Shares (NNNN) vs Cartesian Therapeutics, Inc. (RNAC)
A side-by-side comparison of Anbio Biotechnology Class A Ordinary Shares and Cartesian Therapeutics, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
NNNN
Anbio Biotechnology Class A Ordinary Shares
$4.90HealthcareDelayed quote: Oct 6, 2026, 12:23 PM EDT
RNAC
Cartesian Therapeutics, Inc.
$7.13HealthcareDelayed quote: Oct 6, 2026, 12:25 PM EDT
Total return — NNNN vs RNAC
growth of $100 · dividends reinvested · last 2yNNNN -16.3% (-8.5%/yr)RNAC -63.7% (-39.8%/yr)NNNN compounded faster over this window
NNNN RNAC
NNNN vs RNAC: by the numbers
- •NNNN is the larger company ($215M vs $209M market cap).
- •NNNN is profitable (74.06% net margin) while RNAC runs a net loss (-10422.48%).
Metrics side by side
Valuation
| Metric | NNNN | RNAC |
|---|---|---|
| P/S ratio | N/A | 141.83 |
| P/B ratio | 7.13 | N/A |
Profitability
| Metric | NNNN | RNAC |
|---|---|---|
| Gross margin | 87.24% | 100.00% |
| Operating margin | 66.70% | -3099.93% |
| Net margin | 74.06% | -10422.48% |
| ROE | 21.24% | N/A |
| ROIC | 19.13% | -33.10% |
Growth (annualized)
| Metric | NNNN | RNAC |
|---|---|---|
| Revenue CAGR (5Y) | N/A | -50.01% |
| Total return CAGR (5Y) | N/A | -44.03% |
Frequently asked
- Is NNNN or RNAC more profitable?
- NNNN runs the higher net margin — NNNN at 74.06% versus RNAC at -10422.48%.
Go deeper
Dig into the metrics
Anbio Biotechnology Class A Ordinary Shares ROECartesian Therapeutics ROEAnbio Biotechnology Class A Ordinary Shares operating marginCartesian Therapeutics operating marginAnbio Biotechnology Class A Ordinary Shares revenue growthCartesian Therapeutics revenue growthAnbio Biotechnology Class A Ordinary Shares free cash flowCartesian Therapeutics free cash flow
Anbio Biotechnology Class A Ordinary Shares & Cartesian Therapeutics appear in these rankings
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.